Table 2 Univariate analysis for outcome variables according to conditioning protocol.

From: Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party

Outcomes at 2 years

Entire cohort

FluMel

FBM/FTM

Estimate (95%CI)

Estimate (95%CI)

Estimate (95%CI)

OS

60.1% (57–63.1)

58.1% (54.5–61.5)

68.3% (61.3–74.3)

LFS

55.2% (52.0–58.2)

54.1% (50.6–57.5)

59.4% (52.2–65.8)

RI

23.9% (21.4–26.6)

23.7% (20.8–26.6)

24.9% (19.1–31.1)

NRM

20.9% (18.5–23.4)

22.2% (19.4–25.1)

15.8% (11.2–21.0)

aGvHD II–IV (100d)

25.5% (23.1–28.0)

22.3% (19.7–25.0)

36.9% (31.0–42.7)

aGvHD III–IV (100d)

9.0% (7.5–10.7)

7.5% (5.9–9.3)

14.4% (10.5–19.0)

cGvHD

32.8% (29.9–35.7)

32.3% (29.1–35.6)

34.5% (28.2–41.0)

cGvHD Ext.

10.3% (8.5–12.3)

9.8% (7.8–12.0)

12.4% (8.2–17.5)

GRFS

45.9% (42.8–48.9)

45.9% (42.5–49.4)

45.7% (38.8–52.4)

  1. OS overall survival, LFS leukemia-free survival, RI relapse incidence, NRM non-relapse mortality, aGvHD acute graft-versus-host disease, cGvHD chronic graft-versus-host disease, Ext extensive, GRFS GvHD-/relapse-free survival, FluMel fludarabine/melphalan, FBM fludarabine/BCNU/melphalan, FTM fludarabine/thiotepa/melphalan, CI confidence interval, d day, y year.
  2. *Outcomes were censored at 2 years except aGvHD, which was censored at 100 days.
Back to article page